author-photo

Kazuo Nakagawa

Kindai University

35

Papers

175

Citations

Citation Trend

Filter By

Papers (35) Sort By

JournalConferenceOthers

Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (26)
OA03.07 Pembrolizumab for Advanced Mesothelioma: Results from the Phase 2 KEYNOTE-158 Study

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
RELAY : étude de phase 3 internationale en double aveugle et randomisée comparant l’erlotinib (ERL) associé au ramucirumab (RAM) ou à un placebo (PL) comme traitement de première ligne chez des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) métastatique avec une mutation du récepteur du facteur de croissance épidermique (EGFRm)

2020 Revue des Maladies Respiratoires Actualités
Show All
- Source
- Cite
- Save
Citations (0)
480PSafety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050

2019 Annals of Oncology
- T.S.K. Mok
- Ying Cheng
- X. Zhou
- K.H. Lee
- Kazuo Nakagawa
- Seiji Niho
- Rafael Rosell
- R. Linke
- C.H. Wong
- Yiyun Tang
- M. Singh
- Keith D. Wilner
- Y-L. Wu
Show All
- Source
- Cite
- Save
Citations (1)
LBA19Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (9)
479OPatient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1544PThe safety assessment of crizotinib and alectinib from real-world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P1.01-103 Preliminary Results of Brigatinib in Japanese Patients (Pts) Who Previously Received Alectinib: Brigatinib-2001 Study

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
MA03.11 Chemotherapy After PD-1 Inhibitors Versus Chemotherapy Alone in Patients with Non–Small Cell Lung Cancer (WJOG10217L)

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (54)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号